Claustrat B, Leston J. Melatonin: physiological effects in humans.Neurochirurgie. 2015;61:77–84. [DOI] [PubMed]
Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, et al. Melatonin: pharmacology, functions and therapeutic benefits.Curr Neuropharmacol. 2017;15:434–43. [DOI] [PubMed] [PMC]
Arendt J, Aulinas A. Physiology of the pineal gland and melatonin. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000. [PubMed]
Choi D. Potency of melatonin in living beings.Dev Reprod. 2013;17:149–77. [DOI] [PubMed] [PMC]
Poeggeler B, Saarela S, Reiter RJ, Tan DX, Chen LD, Manchester LC, et al. Melatonin—a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro.Ann N Y Acad Sci. 1994;738:419–20. [DOI] [PubMed]
Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers.J Pineal Res. 2016;61:253–78. [DOI] [PubMed]
Reiter RJ, Sharma R, Ma Q, Rosales-Corral SA, Acuña-Castroviejo D, Escames G. Inhibition of mitochondrial pyruvate dehydrogenase kinase: a proposed mechanism by which melatonin causes cancer cells to overcome cytosolic glycolysis, reduce tumor biomass and reverse insensitivity to chemotherapy.Melatonin Res. 2019;2:105–19. [DOI]
Anderson G. Daytime orexin and night-time melatonin regulation of mitochondria melatonin: roles in circadian oscillations systemically and centrally in breast cancer symptomatology.Melatonin Res. 2019;2:1–8. [DOI]
Anderson G. Why do anti-amyloid beta antibodies not work? Time to reconceptualize dementia pathophysiology by incorporating astrocyte melatonergic pathway desynchronization from amyloid-beta production.Braz J Psychiatry. 2023;45:89–92. [DOI] [PubMed] [PMC]
Karasek M, Reiter RJ. Melatonin and aging.Neuro Endocrinol Lett. 2002;23:14–6. [PubMed]
Martín Giménez VM, de Las Heras N, Lahera V, Tresguerres JAF, Reiter RJ, Manucha W. Melatonin as an anti-aging therapy for age-related cardiovascular and neurodegenerative diseases.Front Aging Neurosci. 2022;14:888292. [DOI] [PubMed] [PMC]
Tresguerres IF, Tamimi F, Eimar H, Barralet JE, Prieto S, Torres J, et al. Melatonin dietary supplement as an anti-aging therapy for age-related bone loss.Rejuvenation Res. 2014;17:341–6. [DOI] [PubMed]
Reiter RJ, Tan DX, Sainz RM, Mayo JC. Melatonin protects the heart against both ischemia/reperfusion injury and chemotherapeutic drugs.Cardiovasc Drugs Ther. 2002;16:5–6. [DOI] [PubMed]
Li Y, Li S, Zhou Y, Meng X, Zhang JJ, Xu DP, et al. Melatonin for the prevention and treatment of cancer.Oncotarget. 2017;8:39896–921. [DOI] [PubMed] [PMC]
Talib WH, Alsayed AR, Abuawad A, Daoud S, Mahmod AI. Melatonin in cancer treatment: current knowledge and future opportunities.Molecules. 2021;26:2506. [DOI] [PubMed] [PMC]
Wang L, Wang C, Choi WS. Use of melatonin in cancer treatment: where are we?Int J Mol Sci. 2022;23:3779. [DOI] [PubMed] [PMC]
Tan DX, Manchester LC, Qin L, Reiter RJ. Melatonin: a mitochondrial targeting molecule involving mitochondrial protection and dynamics.Int J Mol Sci. 2016;17:2124. [DOI] [PubMed] [PMC]
Lowes DA, Webster NR, Murphy MP, Galley HF. Antioxidants that protect mitochondria reduce interleukin-6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsis.Br J Anaesth. 2013;110:472–80. [DOI] [PubMed] [PMC]
Haus E, Touitou Y. Principles of clinical chronobiology.In: Touitou Y, Haus E, editors. Biologic rhythms in clinical and laboratory medicine. 2nd ed. Berlin, Heidelberg: Springer Berlin Heidelberg; 1992. pp. 6–34. [DOI]
Schulz P, Steimer T. Neurobiology of circadian systems.CNS Drugs. 2009;23:3–13. [DOI] [PubMed]
Uluoglu C. Melatonin: a cbronoblotic with antiaging properties.Turk Klin J Med Sci. 2008;28:S84–7.
Lee Y, Field JM, Sehgal A. Circadian rhythms, disease and chronotherapy.J Biol Rhythms. 2021;36:503–31. [DOI] [PubMed] [PMC]
Gooley JJ, Saper CB. Anatomy of the mammalian circadian system. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine (fourth edition). Philadelphia: W.B. Saunders; 2005. pp. 335–50. [DOI]
Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation.Br J Pharmacol. 2018;175:3190–9. [DOI] [PubMed] [PMC]
Walker WH 2nd, Walton JC, DeVries AC, Nelson RJ. Circadian rhythm disruption and mental health.Transl Psychiatry. 2020;10:28. [DOI] [PubMed] [PMC]
Guney Y, Hicsonmez A, Uluoglu C, Guney HZ, Ozel Turkcu U, Take G, et al. Melatonin prevents inflammation and oxidative stress caused by abdominopelvic and total body irradiation of rat small intestine.Braz J Med Biol Res. 2007;40:1305–14. [DOI] [PubMed]
Take G, Erdogan D, Helvacioglu F, Göktas G, Ozbey G, Uluoglu C, et al. Effect of melatonin and time of administration on irradiation-induced damage to rat testes.Braz J Med Biol Res. 2009;42:621–8. [DOI] [PubMed]
Lee JG, Woo YS, Park SW, Seog DH, Seo MK, Bahk WM. The neuroprotective effects of melatonin: possible role in the pathophysiology of neuropsychiatric disease.Brain Sci. 2019;9:285.Erratum in: Brain Sci. 2019;9:341. [DOI] [PubMed] [PMC]
Esposito E, Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system.Curr Neuropharmacol. 2010;8:228–42. [DOI] [PubMed] [PMC]
Jo SH, Lee SH, Kim KT, Choi SY. Melatonin inhibits nicotinic acetylcholine receptor functions in bovine chromaffin cells.Int J Oral Biol. 2019;44:50–4. [DOI]
Barajas-López C, Peres AL, Espinosa-Luna R, Reyes-Vázquez C, Prieto-Gómez B. Melatonin modulates cholinergic transmission by blocking nicotinic channels in the guinea-pig submucous plexus.Eur J Pharmacol. 1996;312:319–25. [DOI] [PubMed]
Pham L, Baiocchi L, Kennedy L, Sato K, Meadows V, Meng F, et al. The interplay between mast cells, pineal gland, and circadian rhythm: links between histamine, melatonin, and inflammatory mediators.J Pineal Res. 2021;70:e12699. [DOI] [PubMed] [PMC]
Wadas B, Borjigin J, Huang Z, Oh JH, Hwang CS, Varshavsky A. Degradation of serotonin N-acetyltransferase, a circadian regulator, by the N-end rule pathway.J Biol Chem. 2016;291:17178–96. [DOI] [PubMed] [PMC]
Klein DC, Coon SL, Roseboom PH, Weller JL, Bernard M, Gastel JA, et al. The melatonin rhythm-generating enzyme: molecular regulation of serotonin N-acetyltransferase in the pineal gland.Recent Prog Horm Res. 1997;52:307–57. [PubMed]
Lewczuk B, Nowicki M, Prusik M, Przybylska-Gornowicz B. Diurnal rhythms of pinealocyte ultrastructure, pineal serotonin content and plasma melatonin level in the domestic pig.Folia Histochem Cytobiol. 2004;42:155–63. [PubMed]
Snyder SH, Zweig M, Axelrod J, Fischer JE. Control of the circadian rhythm in serotonin content of the rat pineal gland.Proc Natl Acad Sci U S A. 1965;53:301–5. [DOI] [PubMed] [PMC]
Jang SW, Liu X, Pradoldej S, Tosini G, Chang Q, Iuvone PM, et al. N-Acetylserotonin activates TrkB receptor in a circadian rhythm.Proc Natl Acad Sci U S A. 2010;107:3876–81. [DOI] [PubMed] [PMC]
Deurveilher S, Semba K. Indirect projections from the suprachiasmatic nucleus to major arousal-promoting cell groups in rat: implications for the circadian control of behavioural state.Neuroscience. 2005;130:165–83. [DOI] [PubMed]
Morin LP, Allen CN. The circadian visual system, 2005.Brain Res Rev. 2006;51:1–60. [DOI] [PubMed]
Glass JD, Grossman GH, Farnbauch L, DiNardo L. Midbrain raphe modulation of nonphotic circadian clock resetting and 5-HT release in the mammalian suprachiasmatic nucleus.J Neurosci. 2003;23:7451–60. [DOI] [PubMed] [PMC]
Loving RT, Kripke DF, Shuchter SR. Bright light augments antidepressant effects of medication and wake therapy.Depress Anxiety. 2002;16:1–3. [DOI] [PubMed]
Gorwood P. Restoring circadian rhythms: a new way to successfully manage depression.J Psychopharmacol. 2010;24:15–9. [DOI] [PubMed]
Comai S, Gobbi G. CCNP award paper: unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology.J Psychiatry Neurosci. 2014;39:6–21. [DOI] [PubMed] [PMC]
Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression.Lancet. 2011;378:621–31. [DOI] [PubMed]
McGlashan EM, Nandam LS, Vidafar P, Mansfield DR, Rajaratnam SMW, Cain SW. The SSRI citalopram increases the sensitivity of the human circadian system to light in an acute dose.Psychopharmacology (Berl). 2018;235:3201–9. [DOI] [PubMed]
Varma A, Kaul RK, Varma P, Kalra V, Malhotra V. The effect of antidepressants on serum melatonin levels in endogenous depression.J Assoc Physicians India. 2002;50:1262–5. [PubMed]
Silva S, Bicker J, Falcão A, Fortuna A. Antidepressants and circadian rhythm: exploring their bidirectional interaction for the treatment of depression.Pharmaceutics. 2021;13:1975. [DOI] [PubMed] [PMC]
Tan DX, Manchester LC, Liu X, Rosales-Corral SA, Acuna-Castroviejo D, Reiter RJ. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin’s primary function and evolution in eukaryotes.J Pineal Res. 2013;54:127–38. [DOI] [PubMed]
Linsell CR, Lightman SL, Mullen PE, Brown MJ, Causon RC. Circadian rhythms of epinephrine and norepinephrine in man.J Clin Endocrinol Metab. 1985;60:1210–5. [DOI] [PubMed]
Simonneaux V, Ribelayga C. Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters.Pharmacol Rev. 2003;55:325–95. [DOI] [PubMed]
Leach S, Suzuki K. Adrenergic signaling in circadian control of immunity.Front Immunol. 2020;11:1235. [DOI] [PubMed] [PMC]
Schomerus C, Korf HW. Mechanisms regulating melatonin synthesis in the mammalian pineal organ.Ann N Y Acad Sci. 2005;1057:372–83. [DOI] [PubMed]
Mitchell HA, Weinshenker D. Good night and good luck: norepinephrine in sleep pharmacology.Biochem Pharmacol. 2010;79:801–9. [DOI] [PubMed] [PMC]
Ross JA, Van Bockstaele EJ. The locus coeruleus- norepinephrine system in stress and arousal: unraveling historical, current, and future perspectives.Front Psychiatry. 2020;11:601519. [DOI] [PubMed] [PMC]
Korshunov KS, Blakemore LJ, Trombley PQ. Dopamine: a modulator of circadian rhythms in the central nervous system.Front Cell Neurosci. 2017;11:91. [DOI] [PubMed] [PMC]
Goel M, Mangel SC. Dopamine-mediated circadian and light/dark-adaptive modulation of chemical and electrical synapses in the outer retina.Front Cell Neurosci. 2021;15:647541. [DOI] [PubMed] [PMC]
Corthell JT, Stathopoulos AM, Watson CC, Bertram R, Trombley PQ. Olfactory bulb monoamine concentrations vary with time of day.Neuroscience. 2013;247:234–41. [DOI] [PubMed] [PMC]
Doyle SE, Grace MS, McIvor W, Menaker M. Circadian rhythms of dopamine in mouse retina: the role of melatonin.Vis Neurosci. 2002;19:593–601. [DOI] [PubMed]
Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting.Cell Mol Neurobiol. 2001;21:605–16. [DOI] [PubMed]
Okatani Y, Sagara Y. Role of melatonin in nocturnal prolactin secretion in women with normoprolactinemia and mild hyperprolactinemia.Am J Obstet Gynecol. 1993;168:854–61. [DOI] [PubMed]
Escames G, Macías M, León J, García J, Khaldy H, Martín M, et al. Calcium-dependent effects of melatonin inhibition of glutamatergic response in rat striatum.J Neuroendocrinol. 2001;13:459–66. [DOI] [PubMed]
Exposito I, Mora F, Zisapel N, Oaknin S. The modulatory effect of melatonin on the dopamine-glutamate interaction in the anterior hypothalamus during ageing.Neuroreport. 1995;6:2399–403. [DOI] [PubMed]
Willis GL, Armstrong SM. A therapeutic role for melatonin antagonism in experimental models of Parkinson’s disease.Physiol Behav. 1999;66:785–95. [DOI] [PubMed]
Viganò D, Lissoni P, Rovelli F, Roselli MG, Malugani F, Gavazzeni C, et al. A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia.Neuro Endocrinol Lett. 2001;22:137–41. [PubMed]
Bersani G, Mameli M, Garavini A, Pancheri P, Nordio M. Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia.Neuro Endocrinol Lett. 2003;24:181–4. [PubMed]
Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects.Metab Brain Dis. 2012;27:113–9. [DOI] [PubMed]
Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study.Arch Gen Psychiatry. 2001;58:1049–52. [DOI] [PubMed]
Castro F, Carrizo E, Prieto de Rincón D, Rincón CA, Asián T, Medina-Leendertz S, et al. Effectiveness of melatonin in tardive dyskinesia.Invest Clin. 2011;52:252–60. [PubMed]
Shamir E, Barak Y, Plopsky I, Zisapel N, Elizur A, Weizman A. Is melatonin treatment effective for tardive dyskinesia?J Clin Psychiatry. 2000;61:556–8. [DOI] [PubMed]
Hut RA, Van der Zee EA. The cholinergic system, circadian rhythmicity, and time memory.Behav Brain Res. 2011;221:466–80. [DOI] [PubMed]
Davis B, Sadik K. Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy.Dement Geriatr Cogn Disord. 2006;21:120–9. [DOI] [PubMed]
Watson CJ, Baghdoyan HA, Lydic R. Neuropharmacology of sleep and wakefulness.Sleep Med Clin. 2010;5:513–28. [DOI] [PubMed] [PMC]
Brown RE, Basheer R, McKenna JT, Strecker RE, McCarley RW. Control of sleep and wakefulness.Physiol Rev. 2012;92:1087–187. [DOI] [PubMed] [PMC]
Chen BH, Park JH, Kim DW, Park J, Choi SY, Kim IH, et al. Melatonin improves cognitive deficits via restoration of cholinergic dysfunction in a mouse model of scopolamine-induced amnesia.ACS Chem Neurosci. 2018;9:2016–24. [DOI] [PubMed]
Markus RP, Silva CL, Franco DG, Barbosa EM Jr, Ferreira ZS. Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs?Pharmacol Ther. 2010;126:251–62. [DOI] [PubMed]
Shukla M, Govitrapong P, Boontem P, Reiter RJ, Satayavivad J. Mechanisms of melatonin in alleviating Alzheimer’s disease.Curr Neuropharmacol. 2017;15:1010–31. [DOI] [PubMed] [PMC]
Sommansson A, Nylander O, Sjöblom M. Melatonin decreases duodenal epithelial paracellular permeability via a nicotinic receptor-dependent pathway in rats in vivo.J Pineal Res. 2013;54:282–91. [DOI] [PubMed]
Fernández-Bachiller MI, Pérez C, Campillo NE, Páez JA, González-Muñoz GC, Usán P, et al. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer’s disease, with cholinergic, antioxidant, and neuroprotective properties.ChemMedChem. 2009;4:828–41. [DOI] [PubMed]
Nishino H, Koizumi K. Responses of neurons in the suprachiasmatic nuclei of the hypothalamus to putative transmitters.Brain Res. 1977;120:167–72. [DOI] [PubMed]
Earnest DJ, Turek FW. Neurochemical basis for the photic control of circadian rhythms and seasonal reproductive cycles: role for acetylcholine.Proc Natl Acad Sci U S A. 1985;82:4277–81. [DOI] [PubMed] [PMC]
Reghunandanan V, Reghunandanan R. Neurotransmitters of the suprachiasmatic nuclei.J Circadian Rhythms. 2006;4:2. [DOI] [PubMed] [PMC]
Thakkar MM. Histamine in the regulation of wakefulness.Sleep Med Rev. 2011;15:65–74. [DOI] [PubMed] [PMC]
Scammell TE, Jackson AC, Franks NP, Wisden W, Dauvilliers Y. Histamine: neural circuits and new medications.Sleep. 2019;42:zsy183. [DOI] [PubMed] [PMC]
Yu X, Zecharia A, Zhang Z, Yang Q, Yustos R, Jager P, et al. Circadian factor BMAL1 in histaminergic neurons regulates sleep architecture.Curr Biol. 2014;24:2838–44. [DOI] [PubMed] [PMC]
Abe H, Honma S, Ohtsu H, Honma K. Circadian rhythms in behavior and clock gene expressions in the brain of mice lacking histidine decarboxylase.Brain Res Mol Brain Res. 2004;124:178–87. [DOI] [PubMed]
Gandhi AV, Mosser EA, Oikonomou G, Prober DA. Melatonin is required for the circadian regulation of sleep.Neuron. 2015;85:1193–9. [DOI] [PubMed] [PMC]
Kawauchi T, Ishimaru K, Nakamura Y, Nakano N, Hara M, Ogawa H, et al. Clock-dependent temporal regulation of IL-33/ST2-mediated mast cell response.Allergol Int. 2017;66:472–8. [DOI] [PubMed]
Maldonado MD, Mora-Santos M, Naji L, Carrascosa-Salmoral MP, Naranjo MC, Calvo JR. Evidence of melatonin synthesis and release by mast cells. Possible modulatory role on inflammation.Pharmacol Res. 2010;62:282–7. [DOI] [PubMed]
Favero G, Franceschetti L, Bonomini F, Rodella LF, Rezzani R. Melatonin as an anti-inflammatory agent modulating inflammasome activation.Int J Endocrinol. 2017;2017:1835195. [DOI] [PubMed] [PMC]
Pala D, Scalvini L, Lodola A, Mor M, Flammini L, Barocelli E, et al. Synthesis and characterization of new bivalent agents as melatonin- and histamine H3-ligands.Int J Mol Sci. 2014;15:16114–33. [DOI] [PubMed] [PMC]
Mihic SJ, Mayfield J. Hypnotics and sedatives. In: Brunton LL, Knollmann BC, editors. Goodman & Gilman’s: the pharmacological basis of therapeutics, 14th edition. New York, NY: McGraw-Hill Education; 2023.
Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.CNS Neurosci Ther. 2009;15:32–51. [DOI] [PubMed] [PMC]
Hirai K, Kita M, Ohta H, Nishikawa H, Fujiwara Y, Ohkawa S, et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats.J Biol Rhythms. 2005;20:27–37. [DOI] [PubMed]
Miyamoto M. Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice.Neurosci Lett. 2006;402:201–4. [DOI] [PubMed]
Wu YH, Zhou JN, Van Heerikhuize J, Jockers R, Swaab DF. Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer’s disease.Neurobiol Aging. 2007;28:1239–47. [DOI] [PubMed]
Srinivasan V, Kaur C, Pandi-Perumal S, Brown GM, Cardinali DP. Melatonin and its agonist ramelteon in Alzheimer’s disease: possible therapeutic value.Int J Alzheimers Dis. 2010;2011:741974. [DOI] [PubMed] [PMC]
Reiter RJ, Cabrera J, Sainz RM, Mayo JC, Manchester LC, Tan DX. Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington’s disease, Alzheimer’s disease and parkinsonism.Ann N Y Acad Sci. 1999;890:471–85. [DOI] [PubMed]
Imbesi M, Uz T, Dzitoyeva S, Manev H. Stimulatory effects of a melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cells.Neurosci Lett. 2008;439:34–6. [DOI] [PubMed]
Hatta K, Kishi Y, Wada K, Takeuchi T, Hashimoto N, Suda K, et al. Real-world effectiveness of ramelteon and suvorexant for delirium prevention in 948 patients with delirium risk factors.J Clin Psychiatry. 2019;81:19m12865. [DOI] [PubMed]
Osanai K, Kobayashi Y, Otsu M, Izawa T, Sakai K, Iwashita M. Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells.Hum Cell. 2017;30:209–15. [DOI] [PubMed]
Kast RE. Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers.Contemp Oncol (Pozn). 2015;19:157–62. [DOI] [PubMed] [PMC]
Mathes AM, Kubulus D, Waibel L, Weiler J, Heymann P, Wolf B, et al. Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in rat.Crit Care Med. 2008;36:2863–70. [DOI] [PubMed]
Kennedy SH, Eisfeld BS. Agomelatine and its therapeutic potential in the depressed patient.Neuropsychiatr Dis Treat. 2007;3:423–8. [PubMed] [PMC]
Prajapati JB, Verma SD, Patel AA. Oral bioavailability enhancement of agomelatine by loading into nanostructured lipid carriers: Peyer’s patch targeting approach.Int J Nanomedicine. 2018;13:35–8. [DOI] [PubMed] [PMC]
Satyanarayanan SK, Su H, Lin YW, Su KP. Circadian rhythm and melatonin in the treatment of depression.Curr Pharm Des. 2018;24:2549–55. [DOI] [PubMed]
Martinet L, Guardiola-Lemaitre B, Mocaer E. Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent.Pharmacol Biochem Behav. 1996;54:713–8. [DOI] [PubMed]
Redman JR, Francis AJ. Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal.J Biol Rhythms. 1998;13:39–51. [DOI] [PubMed]
Van Reeth O, Olivares E, Turek FW, Granjon L, Mocaer E. Resynchronisation of a diurnal rodent circadian clock accelerated by a melatonin agonist.Neuroreport. 1998;9:1901–5. [DOI] [PubMed]
Mairesse J, Silletti V, Laloux C, Zuena AR, Giovine A, Consolazione M, et al. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats.Int J Neuropsychopharmacol. 2013;16:323–38. [DOI] [PubMed]
Quera Salva MA, Vanier B, Laredo J, Hartley S, Chapotot F, Moulin C, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study.Int J Neuropsychopharmacol. 2007;10:691–6. [DOI] [PubMed]
Dubocovich ML. Agomelatine targets a range of major depressive disorder symptoms.Curr Opin Investig Drugs. 2006;7:670–80. [PubMed]
Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaër E. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.Br J Pharmacol. 2014;171:3604–19. [DOI] [PubMed] [PMC]
Papp M, Litwa E, Gruca P, Mocaër E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety.Behav Pharmacol. 2006;17:9–18. [PubMed]
Stein DJ, Ahokas A, Jarema M, Avedisova AS, Vavrusova L, Chaban O, et al. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study.Eur Neuropsychopharmacol. 2017;27:526–37. [DOI] [PubMed]
Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis.Lancet. 2019;393:768–77.Erratum in: Lancet. 2019;393:1698. [DOI] [PubMed]
Su Q, Li T, Liu GW, Zhang YL, Guo JH, Wang ZJ, et al. Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease.Neural Regen Res. 2023;18:727–33. [DOI] [PubMed] [PMC]
Bertaina-Anglade V, Drieu-La-Rochelle C, Mocaër E, Seguin L. Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat.Pharmacol Biochem Behav. 2011;98:511–7. [DOI] [PubMed]
Ladurelle N, Gabriel C, Viggiano A, Mocaër E, Baulieu EE, Bianchi M. Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.Psychopharmacology (Berl). 2012;221:493–509. [DOI] [PubMed]
Molteni R, Calabrese F, Pisoni S, Gabriel C, Mocaer E, Racagni G, et al. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration.World J Biol Psychiatry. 2010;11:148–53. [DOI] [PubMed]
Tang SW, Helmeste D, Leonard B. Is neurogenesis relevant in depression and in the mechanism of antidepressant drug action? A critical review.World J Biol Psychiatry. 2012;13:402–12. [DOI] [PubMed]
Soumier A, Banasr M, Lortet S, Masmejean F, Bernard N, Kerkerian-Le-Goff L, et al. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus.Neuropsychopharmacology. 2009;34:2390–403. [DOI] [PubMed]
Yao K, Zhao YF, Zu HB. Melatonin receptor stimulation by agomelatine prevents Aβ-induced tau phosphorylation and oxidative damage in PC12 cells.Drug Des Devel Ther. 2019;13:387–96. [DOI] [PubMed] [PMC]
Wang CS, Cheng KS, Tang CH, Pai MC, Chen PL, Chien PF. The effect of agomelatine in behavioral and psychological symptoms of dementia.Clin Psychopharmacol Neurosci. 2022;20:701–14. [DOI] [PubMed] [PMC]
Moreno-SanJuan S, Puentes-Pardo JD, Casado J, Escudero-Feliu J, Khaldy H, Arnedo J, et al. Agomelatine, a melatonin-derived drug, as a new strategy for the treatment of colorectal cancer.Antioxidants (Basel). 2023;12:926. [DOI] [PubMed] [PMC]
de Carnevale Galeti AO, de Oliveira JG, Pinheiro MGM, Bastos dos Santos M, Colombo J, Chuffa LGA, et al. Verification of agomelatine in comparison with melatonin as a therapeutic agent to treat breast cancer.Melatonin Research. 2021;4:141–51. [DOI]
Tavartkiladze A, Revazishvili P, Gvajaia A. Influence of agomelatine and trastuzumab on the HER2/neu(+), MT1 (+) and MT2 (+) chemo and immunoresistant breast cancer cells lines from the previously treated patients by targeted therapy with trastuzumab.J Clin Oncol. 2019;37:e14056. [DOI]
Hong N, Ye Z, Lin Y, Liu W, Xu N, Wang Y. Agomelatine prevents angiotensin II-induced endothelial and mononuclear cell adhesion.Aging (Albany NY). 2021;13:18515–26. [DOI] [PubMed] [PMC]
Štuhec M. Agomelatine-induced hepatotoxicity.Wien Klin Wochenschr. 2013;125:225–6. [DOI] [PubMed]
Friedrich ME, Akimova E, Huf W, Konstantinidis A, Papageorgiou K, Winkler D, et al. Drug-induced liver injury during antidepressant treatment: results of AMSP, a drug surveillance program.Int J Neuropsychopharmacol. 2016;19:pyv126. [DOI] [PubMed] [PMC]
Keating GM. Tasimelteon: a review in non-24-hour sleep-wake disorder in totally blind individuals.CNS Drugs. 2016;30:461–8. [DOI] [PubMed]
Lavedan C, Forsberg M, Gentile AJ. Tasimelteon: a selective and unique receptor binding profile.Neuropharmacology. 2015;91:142–7. [DOI] [PubMed]
Lockley SW, Dressman MA, Licamele L, Xiao C, Fisher DM, Flynn-Evans EE, et al. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.Lancet. 2015;386:1754–64. [DOI] [PubMed]
Carocci A, Catalano A, Sinicropi MS. Melatonergic drugs in development.Clin Pharmacol. 2014;6:127–37. [DOI] [PubMed] [PMC]
Paulis L, Simko F, Laudon M. Cardiovascular effects of melatonin receptor agonists.Expert Opin Investig Drugs. 2012;21:1661–78. [DOI] [PubMed]
Khan S, Khurana M, Vyas P, Vohora D. The role of melatonin and its analogues in epilepsy.Rev Neurosci. 2021;32:49–67. [DOI] [PubMed]
She M, Deng X, Guo Z, Laudon M, Hu Z, Liao D, et al. NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats.Pharmacol Res. 2009;59:248–53. [DOI] [PubMed]
Tian SW, Laudon M, Han L, Gao J, Huang FL, Yang YF, et al. Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models.Acta Pharmacol Sin. 2010;31:775–83. [DOI] [PubMed] [PMC]
He P, Ouyang X, Zhou S, Yin W, Tang C, Laudon M, et al. A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer’ disease.Horm Behav. 2013;64:1–7. [DOI] [PubMed]
Buendia I, Gómez-Rangel V, González-Lafuente L, Parada E, León R, Gameiro I, et al. Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models.Neuropharmacology. 2015;99:187–95. [DOI] [PubMed]
Li X, He J, Li X, Li Y, Zhou Y, Cai S. Neu-P11 — a novel melatonin receptor agonist, could improve the features of type-2 diabetes mellitus in rats.Endokrynol Pol. 2021;72:634–42. [DOI] [PubMed]
Zhou J, Zhang J, Luo X, Li M, Yue Y, Laudon M, et al. Neu-P11, a novel MT1/MT2 agonist, reverses diabetes by suppressing the hypothalamic-pituitary-adrenal axis in rats.Eur J Pharmacol. 2017;812:225–33. [DOI] [PubMed]
Bustamante-García R, Naranjo-Rodríguez EB, Lira-Rocha AS, Ortiz-Osornio A, Picazo O. Behavioural actions of two new 1-N substituted analogues of melatonin.Behav Brain Res. 2013;236:148–56. [DOI] [PubMed]
Ochoa-Sanchez R, Comai S, Lacoste B, Bambico FR, Dominguez-Lopez S, Spadoni G, et al. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand.J Neurosci. 2011;31:18439–52. [DOI] [PubMed] [PMC]
Ochoa-Sanchez R, Rainer Q, Comai S, Spadoni G, Bedini A, Rivara S, et al. Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: comparison with melatonin and diazepam.Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:318–25. [DOI] [PubMed]
Emet M, Ozcan H, Ozel L, Yayla M, Halici Z, Hacimuftuoglu A. A review of melatonin, its receptors and drugs.Eurasian J Med. 2016;48:135–41. [DOI] [PubMed] [PMC]
